10 research outputs found
Five microRNAs in Serum Are Able to Differentiate Breast Cancer Patients From Healthy Individuals
Breast cancer is the cancer with the most incidence and mortality in women. microRNAs
are emerging as novel prognosis/diagnostic tools. Our aim was to identify a serum
microRNA signature useful to predict cancer development. We focused on studying
the expression levels of 30 microRNAs in the serum of 96 breast cancer patients vs.
92 control individuals. Bioinformatic studies provide a microRNA signature, designated
as a predictor, based on the expression levels of five microRNAs. Then, we tested the
predictor in a group of 60 randomly chosen women. Lastly, a proteomic study unveiled
the overexpression and downregulation of proteins differently expressed in the serum of
breast cancer patients vs. that of control individuals. Twenty-six microRNAs differentiate
cancer tissue from healthy tissue, and 16 microRNAs differentiate the serum of cancer
patients from that of the control group. The tissue expression of miR-99a, miR-497,
miR-362, and miR-1274, and the serum levels of miR-141 correlated with patient survival.
Moreover, the predictor consisting of miR-125b, miR-29c, miR-16, miR-1260, and
miR-451 was able to differentiate breast cancer patients from controls. The predictor was
validated in 20 new cases of breast cancer patients and tested in 60 volunteer women,
assigning 11 out of 60 women to the cancer group. An association of low levels of miR-16
with a high content of CD44 protein in serum was found. Circulating microRNAs in serum
can represent biomarkers for cancer prediction. Their clinical relevance and the potential
use of the predictor here described are discussed
Five microRNAs in Serum Are Able to Differentiate Breast Cancer Patients From Healthy Individuals
Càncer de mama; Diagnòstic; SèrumCáncer de mama; Diagnóstico; SueroBreast cancer; Diagnosis; SerumBreast cancer is the cancer with the most incidence and mortality in women. microRNAs are emerging as novel prognosis/diagnostic tools. Our aim was to identify a serum microRNA signature useful to predict cancer development. We focused on studying the expression levels of 30 microRNAs in the serum of 96 breast cancer patients vs. 92 control individuals. Bioinformatic studies provide a microRNA signature, designated as a predictor, based on the expression levels of five microRNAs. Then, we tested the predictor in a group of 60 randomly chosen women. Lastly, a proteomic study unveiled the overexpression and downregulation of proteins differently expressed in the serum of breast cancer patients vs. that of control individuals. Twenty-six microRNAs differentiate cancer tissue from healthy tissue, and 16 microRNAs differentiate the serum of cancer patients from that of the control group. The tissue expression of miR-99a, miR-497, miR-362, and miR-1274, and the serum levels of miR-141 correlated with patient survival. Moreover, the predictor consisting of miR-125b, miR-29c, miR-16, miR-1260, and miR-451 was able to differentiate breast cancer patients from controls. The predictor was validated in 20 new cases of breast cancer patients and tested in 60 volunteer women, assigning 11 out of 60 women to the cancer group. An association of low levels of miR-16 with a high content of CD44 protein in serum was found. Circulating microRNAs in serum can represent biomarkers for cancer prediction. Their clinical relevance and the potential use of the predictor here described are discussed.This work was supported by ISCIII (Instituto de Salud Carlos III) Ref. FIS PI15/01262, co-financed by the European Regional Development Fund (ERDF) and AECC Project GEC Ref. GC16173720CARR (ML). AF, YG-M, and CM were granted with P-FIS, VHIR, and iP-FIS fellowships, respectively
Five microRNAs in Serum Are Able to Differentiate Breast Cancer Patients From Healthy Individuals
Breast cancer is the cancer with the most incidence and mortality in women. microRNAs are emerging as novel prognosis/diagnostic tools. Our aim was to identify a serum microRNA signature useful to predict cancer development. We focused on studying the expression levels of 30 microRNAs in the serum of 96 breast cancer patients vs. 92 control individuals. Bioinformatic studies provide a microRNA signature, designated as a predictor, based on the expression levels of five microRNAs. Then, we tested the predictor in a group of 60 randomly chosen women. Lastly, a proteomic study unveiled the overexpression and downregulation of proteins differently expressed in the serum of breast cancer patients vs. that of control individuals. Twenty-six microRNAs differentiate cancer tissue from healthy tissue, and 16 microRNAs differentiate the serum of cancer patients from that of the control group. The tissue expression of miR-99a, miR-497, miR-362, and miR-1274, and the serum levels of miR-141 correlated with patient survival. Moreover, the predictor consisting of miR-125b, miR-29c, miR-16, miR-1260, and miR-451 was able to differentiate breast cancer patients from controls. The predictor was validated in 20 new cases of breast cancer patients and tested in 60 volunteer women, assigning 11 out of 60 women to the cancer group. An association of low levels of miR-16 with a high content of CD44 protein in serum was found. Circulating microRNAs in serum can represent biomarkers for cancer prediction. Their clinical relevance and the potential use of the predictor here described are discusse
Five microRNAs in Serum Are Able to Differentiate Breast Cancer Patients From Healthy Individuals
Breast cancer is the cancer with the most incidence and mortality in women. microRNAs
are emerging as novel prognosis/diagnostic tools. Our aim was to identify a serum
microRNA signature useful to predict cancer development. We focused on studying
the expression levels of 30 microRNAs in the serum of 96 breast cancer patients vs.
92 control individuals. Bioinformatic studies provide a microRNA signature, designated
as a predictor, based on the expression levels of five microRNAs. Then, we tested the
predictor in a group of 60 randomly chosen women. Lastly, a proteomic study unveiled
the overexpression and downregulation of proteins differently expressed in the serum of
breast cancer patients vs. that of control individuals. Twenty-six microRNAs differentiate
cancer tissue from healthy tissue, and 16 microRNAs differentiate the serum of cancer
patients from that of the control group. The tissue expression of miR-99a, miR-497,
miR-362, and miR-1274, and the serum levels of miR-141 correlated with patient survival.
Moreover, the predictor consisting of miR-125b, miR-29c, miR-16, miR-1260, and
miR-451 was able to differentiate breast cancer patients from controls. The predictor was
validated in 20 new cases of breast cancer patients and tested in 60 volunteer women,
assigning 11 out of 60 women to the cancer group. An association of low levels of miR-16
with a high content of CD44 protein in serum was found. Circulating microRNAs in serum
can represent biomarkers for cancer prediction. Their clinical relevance and the potential
use of the predictor here described are discussed
β2-AR blockade potentiates MEK1/2 inhibitor effect on HNSCC by regulating the Nrf2-mediated defense mechanism
Exosomes and breast cancer drug resistance
Lymphatic filariasis (LF) is a vector-borne parasitic disease that is being targeted for elimination through mass drug administration (MDA). The co-distribution of Loa loa in Central Africa poses a significant barrier to the expansion of the MDA due to risk of severe adverse events (SAEs) associated with the drug ivermectin that is routinely used. National LF programmes are yet to significantly scale up in co-endemic areas and need a practical approach to make preliminary decisions based on the mapping status and potential treatment strategies. We reviewed relevant data available to WHO and in the literature for LF-L. loa endemic countries to develop a simple method to support the scale-up of MDA to eliminate LF. A basic model for national LF programmes to work from at the administrative or implementation unit (IU) level has been developed for LF - L. loa co-endemic countries. The model includes five practical steps, which comprise the development of a national filarial database and a simple classification system to help determine the mapping status and most appropriate treatment strategy. Steps are colour-coded and linked to a general decision tree, which is also presented. This IU-level model is simple to follow and will help LF elimination programmes develop an action plan and scale up the implementation of alternative treatment strategies in L. loa co-endemic areas. The model could be further developed to incorporate the additional complexity of IUs where an intervention is required to eliminate onchocerciasis, particularly in hypo-endemic areas where ivermectin has not been used